Immunosuppression in pancreas transplantation: Progress, problems and perspective

Transplant Immunology

Volumn 6, Issue 2, 1998, Pages 69-77

  Stratta, Robert J ^a  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CORTICOSTEROID; CYCLOSPORIN; CYCLOSPORIN A; IMMUNOSUPPRESSIVE AGENT; MONOCLONAL ANTIBODY; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; POLYCLONAL ANTIBODY; TACROLIMUS;

CLINICAL PROTOCOL; GRAFT FAILURE; GRAFT SURVIVAL; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY TRANSPLANTATION; PANCREAS TRANSPLANTATION; PRIORITY JOURNAL; REVIEW; SURVIVAL;

EID: 0031665668     PISSN: 09663274     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0966-3274(98)80020-8     Document Type: Article

References (67)

1. Stratta R.J., Larsen J.L., Cushing K. Pancreas transplantation for diabetes mellitus. Annu Rev Med. 46:1995;281-298.
2. Gruessner A, Sutherland D.E.R. Pancreas transplantation in the United States (US) and non-US as reported to the United Network for Organ Sharing (UNOS) and the International Pancreas Transplant Registry (IPTR). Cecka J.M., Terasaki P.I. Clinical Transplants 1996. 1994;47-67 UCLA Tissue Typing Laboratory, Los Angeles.
3. Sollinger H.W., Stratta R.J., Kalayoglu M, et al. Pancreas transplantation with pancreaticocystostomy and quadruple immunosuppression. Surgery. 102:1987;674-679.
4. Wadstrom J, Brekke B, Wrammer L, et al. Triple versus quadruple induction immunosuppression in pancreas transplantation. Transplant Proc. 27:1995;1317-1318.
5. Brayman K.L., Egidi M.F., Naji A.L., et al. Is induction therapy necessary for successful simultaneous pancreas and kidney transplantation in the cyclosporine era? Transplant Proc. 26:1994;2525-2527.
6. Cantarovich D, Karam G, Hourmant M, et al. Randomized comparison of triple therapy versus anti-thymocyte globulin induction following combined pancreas-renal transplantation. The International Congress on Immunosuppression, Orlando, Florida. December 1997;11-13.
7. Stratta R.J., Taylor R.K., Lowell J.A., et al. OKT3-induction in 100 consecutive pancreas transplants. Transplant Proc. 26:1994;546-547.
8. Stratta R.J., Taylor R.J., Weide L.G., et al. A prospective randomized trial of OKT3 versus ATGAM-induction therapy in pancreas transplant recipients. Transplant Proc. 28:1996;917-918.
9. Knechtle S.J., Pirsch J.D., Groshek M, et al. OKT3 versus ALG induction therapy in combined pancreas-kidney transplantation. Transplant Proc. 23:1991;1581-1582.
10. Ilner W.D., Theodorakis J, Abendroth D, et al. Quadruple-drug induction therapy in combined renal and pancreatic transplantation: OKT3 versus ATG. Transplant Proc. 22:1990;1586-1587.
11. Sutherland D.E.R., Moudry-Munns K.C., Gruessner A. Pancreas transplant outcome with or without biological anti-T cell therapy for induction immunosuppression with use of cyclosporine. Transplant Proc. 26:1994;2752-2755.
12. Sutherland D.E.R. Immunosuppression for clinical pancreas transplantation. Clin Transplant. 5:1991;549-553.
13. Rosenberg L. Pancreas transplantation with ATG versus OKT3. Transplant Proc. 29:1997;35S-36S.
14. Gruessner R.W.G., Troppmann C, Barrou B. Assessment of donor and recipient risk factors on pancreas transplant outcome. Transplant Proc. 26:1994;437-438.
15. Brayman K.L., Sutherland D.E.R. Factors leading to improved outcome following pancreas transplantation - the influence of immunosuppression and HLA matching. Transplant Proc. 24:1992;91-95.
16. Shapiro M.E., Abrams J.M., Brown R.S., et al. Successful pancreas - renal transplantation without anti-T cell antibody induction. Transplant Proc. 27:1995;3087-3088.
17. Corry R.J., Egidi M.F., Sugitani A, et al. Tacrolimus without anti-lymphocyte induction therapy prevents pancreas loss from rejection in 100 consecutive patients. Acta Diabetol. 34:1997;125.
18. Van Der Pijl J.W., Srivastava N, Denouel J, et al. Pharmacokinetics of the conventional and microemulsion formulations of cyclosporine in pancreas - kidney transplant recipients with gastroparesis. Transplantation. 62:1996;456-462.
19. Storck M, Mickley V, Steinbach G, et al. Cyclosporine resorption in diabetic patients after simultaneous pancreas and kidney transplantation. Transplant Proc. 27:1995;3094-3095.
20. Lang J, Garnier J.L., Faure J.L., et al. Cyclosporine pharmacokinetics in diabetic patients after kidney and pancreas transplantation. Clin Transplant. 3:1989;1-4.
21. Serafinowicz A, Gaciong Z, Baczkowska T, et al. Cyclosporine pharmacokinetics in renal allograft recipients with diabetes mellitus treated with Sandimmune and Sandimmune Neoral. Transplant Proc. 28:1996;3140-3141.
22. Rigotti P, Cadrobbi R, Baldan N, et al. Neoral versus Sandimmune in kidney - pancreas transplantation. Transplant Proc. 29:1997;2924-2926.
23. Chapman J.R., O'Connell P.J., Bovington K.J., Allen R.D.M. Reversal of cyclosporine malabsorption in diabetic recipients of simultaneous pancreas and kidney transplants using a microemulsion formulation. Transplantation. 61:1996;1699-1704.
24. Dawidson I, Ar'rajab A, Lu C, Melone D. Cyclosporine blood levels predict the likelihood of rejection and toxicity after simultaneous pancreas-kidney transplantation. Transplant Proc. 27:1995;134-226.
25. Gruessner R.W.G., Burke G.W., Stratta R.J., et al. Multicentre analysis of the first experience with FK506 for induction and rescue therapy after pancreas transplantation. Transplantation. 61:1996;261-273.
26. Gruessner R.W.G. Tacrolimus in pancreas transplantation: a multicentre analysis. Clin Transplant. 11:1997;299-312.
27. Hariharan S, Munda R, Cavallo T, et al. Rescue therapy with tacrolimus after combined kidney-pancreas and isolated pancreas transplantation in patients with severe cyclosporine nephrotoxicity. Transplantation. 61:1996;1161-1165.
28. Stratta R.J., Taylor R.J., Castaldo P, et al. FK506 induction and rescue therapy in pancreas transplant recipients. Transplant Proc. 28:1996;991-992.
29. Teraoka S, Babazono T, Koike T, et al. Effect of rescue therapy using FK506 on relapsing rejection after combined pancreas and kidney transplantation. Transplant Proc. 27:1995;1335.
30. Shaffer D, Simpson M.A., Conway P, et al. Normal pancreas allograft function following simultaneous pancreas kidney transplantation after rescue therapy with tacrolimus (FK506). Transplantation. 59:1995;1063-1066.
31. Becker J, Witzke O, Friedrich J, et al. Rescue therapy with tacrolimus in simultaneous pancreas-kidney transplantation. Transplant Int. 10:1997;51-54.
32. Demirbas A, Ciancio G, Burke G, et al. FK506 in simultaneous pancreas/kidney transplantation: The University of Miami experience. Transplant Proc. 29:1997;2903.
33. Alloway R.R., Russell W.C., Gaber L.W., et al. Conversion from cyclosporine to tacrolimus in kidney, kidney-pancreas, and pancreas alone transplant recipients: the Memphis experience. Transplant Proc. 28:1996;995-997.
34. Burke G.W., Alejandro R, Ciancio G, et al. The use of FK506 in simultaneous pancreas/kidney transplantation: rescue, induction, and maintenance immunosuppression. Transplant Proc. 27:1995;3123-3124.
35. Peddi V.R., Demmy A.M., Munda R, et al. Use of tacrolimus-based immunosuppression eliminates acute rejection as a major complication following simultaneous kidney and pancreas transplantation. Acta Diabetol. 34:1997;162.
36. Bartlett S.T., Schweitzer E.J., Johnson L.B., et al. Equivalent success of simultaneous pancreas-kidney and solitary pancreas transplantation. A prospective trial of tacrolimus immuno-suppression with percutaneous biopsy. Ann Surg. 224:1996;440-449.
37. Gruessner R.W.G., Sutherland D.E.R., Najarian J.S., et al. Solitary pancreas transplantation for nonuremic patients with labile insulin-dependent diabetes mellitus. Transplantation. 64:1997;1572-1577.
38. US Renal Transplant Mycophenolate Mofetil Study Group Sollinger H.W. Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. Transplantation. 60:1995;225-232.
39. European Mycophenolate Mofetil Cooperative Study Group Placebo-controlled study of mycophenolate mofetil combined with cyclosporine and corticosteroids for prevention of acute rejection. Lancet. 345:1995;1321-1325.
40. Stratta R.J., Taylor R.J., Gill I.S., et al. Mycophenolate mofetil (MMF) induction and conversion therapy in pancreas transplant recipients. American Society of Transplant Physicians, 15th Annual Scientific Meeting, Dallas, TX. 26-29 May 1996.
41. Elkhammas E.A., Yilmaz S, Henry M.L., et al. Combined kidney/pancreas transplantation: comparison of mycophenolate mofetil versus azathioprine. Acta Diabetol. 34:1997;161.
42. Odorico J.S., Pirsch J.D., Knechtle S.J., et al. A study comparing mycophenlate mofetil to azathioprine in simultaneous pancreas-kidney transplantation. Transplantation. 65:1998;240(645A).
43. Gritsch H.A., Egidi M.F., Sugitani A, et al. Comparison of azathioprine and mycophenolate mofetil in pancreas transplantation. Acta Diabetol. 34:1997;162.
44. Marcos A, Ham J.M., Shelden S.L., et al. Mycophenolate mofetil is associated with decreased incidence of severity of acute cellular rejection following simultaneous kidney/pancreas transplant. American Society of Transplant Physicians, 16th Annual Scientific Meeting. Chicago, IL. 10-14 May 1997.
45. FK/MMF Multicentre Study Group Stratta R.J. Simultaneous use of tacrolimus and mycophenolate mofetil in combined pancreas-kidney transplant recipients: a multicentre report. Transplant Proc. 29:1997;654-655.
46. Gruessner R.W.G., Sutherland D.E.R., Drangstveit M.B., Gruessner A.C. Mycophenolate mofetil and tacrolimus in pancreas transplantation. Acta Diabetol. 34:1997;125.
47. Stegall M.D., Simon M, Wachs M, et al. Mycophenolate mofetil decreases rejection in simultaneous pancreas-kidney transplantation when combined with tacrolimus or cyclosporine. Transplantation. 64:1997;1695-1700.
48. Reddy K.S., Stratta R.J., Shokouh-Amiri M.H., et al. Simultaneous kidney-pancreas transplantation without anti-lymphocyte induction. Transplantation. 65:1998;251(691A).
49. Bruce D.S., Woodle E.S., Newell K.A., et al. Effects of tacrolimus, mycophenolate mofetil, and microemulsified cyclosporine on rejection incidence in synchronous pancreas/kidney transplantation. Acta Diabetol. 34:1997;161.
50. Burke G.W., Ciancio G, Alejandro R, et al. The use of tacrolimus and mycophenolate mofetil for pancreas/kidney transplantation with or without OKT3 induction. Transplant Proc. 36:1998;1544-1545.
51. Busing M, Martin D, Schulz T, et al. Mycophenolate mofetil/tacrolimus/single shot ATG versus azathioprine/cyclosporine in pancreas-kidney transplantation: Results of a prospective randomized single-center study. Acta Diabetol. 34:1997;126.
52. Kaufman D.B., DuPuis J, Abecassis M, et al. Results with tacrolimus/mycophenolate mofetil primary maintenance immunosuppression in simultaneous pancreas/kidney transplantation. Acta Diabetol. 34:1997;120.
53. Kahl A, Bechstein W.P., Platz K, et al. First results with a quadruple therapy regimen including tacrolimus and mycophenolate mofetil in patients after combined pancreas and kidney transplantation. Acta Diabetol. 34:1997;162.
54. Lee C.M., Scandling J.D., Pavlakis M, et al. FK506 and mycophenolate mofetil: the superior strategy for simultaneous pancreas-kidney patients. American Society of Transplant Surgeons, 23rd Annual Scientific Meeting, Chicago, IL. 14-16 May 1997.
55. Zucker K, Rosen A, Tsaroucha A, et al. Unexpected augmentation of mycophenolic acid pharmacokinetics in renal transplant patients receiving tacrolimus and mycophenolate mofetil in combination therapy, and analogous in vitro findings. Transplant Immunol. 5:1997;225-232.
56. Larsen JL, Stratta RJ. Consequences of pancreas transplantation. J Invest Med. 42:1994;622-631.
57. Stratta RJ, Taylor RJ, Gill IS. Pancreas transplantation: a managed cure approach to diabetes. Curr Probl Surg. 33:1996;709-816.
58. Cantarovich D, Palneau J, Couderc JP, et al. Maintenance immunosuppression without corticosteroids following combined pancreas and kidney transplantation. Transpl Proc. 23:1991;2224-2225.
59. Hricik DE, Bartucci MR, Mayes JT, Schulak JA. The effects of steroid withdrawal on the lipoprotein in profiles of cyclosporine-treated kidney and kidney-pancreas transplant recipients. Transplantation. 54:1992;868-871.
60. Elmer DS, Fraga D, Stratta RJ, et al. Tacrolimus versus cyclosporin A: effects on glucose utilization in portally drained pancreas allografts. Acta Diabetol. 34:1997;118.
61. Tyden G, Reinholt FP, Sundkvist G, Bolinder J. Recurrence of autoimmune diabetes mellitus in recipients of cadaveric pancreatic grafts. N Engl J Med. 335:1996;860-863.
62. Sutherland DER, Sibley RK, Xu XE, et al. Twin-to-twin pancreas transplantation: reversal and re-enactment of the pathogenesis of Type I diabetes. Trans Assoc Am Physicians. 97:1984;80-87.
63. Larsen JL, Stratta RJ, Miller SA, et al. Evidence that fasting hyperproinsulinemia after combined pancreas-kidney transplantation diminishes over time. Transplantation. 56:1993;1533-1537.
64. Diem P, Abid M, Redmon JB, et al. Systemic venous drainage of pancreas allografts as independent cause of hyperinsulinemia in type I diabetic recipients. Diabetes. 39:1990;534-540.
65. Milde FK, Hart LK, Zehr PS. Pancreatic transplantation: impact on the quality of life of diabetic renal transplant recipients. Diabetes Care. 18:1995;93-95.
66. Hathaway DK, Hartwig MS, Crom DB, Gaber AO. Identification of quality-of-life outcomes distinguishing diabetic kidney-alone and pancreas-kidney recipients. Transplant Proc. 27:1995;3065-3066.
67. Zehrer CI, Gross CR. Quality-of-life of pancreas transplant recipients. Diabetologica. 34:1991;S145-S149.